Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Aug;32(8):1019-26.
doi: 10.1093/sleep/32.8.1019.

Diclofenac potassium restores objective and subjective measures of sleep quality in women with primary dysmenorrhea

Stella Iacovides  1 , Ingrid Avidon, Alison Bentley, Fiona C Baker
Affiliations
Randomized Controlled Trial

Diclofenac potassium restores objective and subjective measures of sleep quality in women with primary dysmenorrhea

Stella Iacovides et al. Sleep. 2009 Aug.

Abstract

Study objectives: Primary dysmenorrhea is a common gynecological disorder that disrupts daytime functioning and nighttime sleep quality. We determined the effectiveness of diclofenac potassium, compared to placebo, in alleviating nighttime pain and restoring sleep architecture in women with primary dysmenorrhea.

Design: Randomized, double-blind, crossover study.

Setting: Sleep laboratory.

Participants: Ten healthy women (21 +/- 1 years) with a history of primary dysmenorrhea.

Interventions: Placebo or diclofenac potassium (150 mg per day) for menstrual pain.

Measurements and results: We assessed objective measures of sleep (polysomnography) and subjective measures of sleep quality, mood, and intensity of menstrual pain. Compared to a pain-free phase of the menstrual cycle (mid-follicular), women receiving placebo for their menstrual pain had a poorer mood (P < 0.01), decreased sleep efficiency (P < 0.05), less REM sleep (P < 0.05), more stage 1 sleep (P < 0.01), and more sleep stage changes per hour of sleep during the night. Administration of diclofenac potassium compared to placebo not only attenuated the women's menstrual pain (P < 0.05), but also increased sleep efficiency (P < 0.05) and percentage of REM sleep (P < 0.01), decreased percentage of stage 1 sleep (P < 0.05) and number of sleep stage changes per hour of sleep (P < 0.05), and improved subjective ratings of sleep quality and morning vigilance (P < 0.05).

Conclusion: Diclofenac potassium effectively attenuates nighttime dysmenorrheic pain and restores subjective and objective measures of sleep quality to values recorded in a pain-free phase of the menstrual cycle.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sleep quality and morning vigilance as measured by the visual analogue scale (VAS, back-transformed data) in 10 women with primary dysmenorrhea when treated with either diclofenac potassium (Pain/Diclofenac) or placebo (Pain/Placebo) during menstruation, and when treated with diclofenac potassium during a pain-free phase of the menstrual cycle (mid-follicular, No-Pain/Diclofenac). *P < 0.05 (RM-ANOVA with a Tukey post hoc test).
See this image and copyright information in PMC

References

    1. Dawood MY. Primary dysmenorrhea: Advances in pathogenesis and management. Obstet Gynecol. 2006;108:428–41. - PubMed
    1. Dawood MY. Dysmenorrhea. J Reprod Med. 1985;30:154–67. - PubMed
    1. Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev. 2002 CD002123. - PMC - PubMed
    1. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage. 2003;25:S21–31. - PubMed
    1. Hofmeyr GJ. Dysmenorrhoea. In: Bassin J, editor. Topics in obstetrics and gynaecology. Johannesburg: Julmar Communications; 1996. pp. 269–74.

Publication types

Substances